Document:

Exhibit 10.1

 

 

 

 

February 4, 2019

 

Mr. Erislandy Dorado-Boladeres

55 Southfied Drive

Belle Mead, NJ 08502

 

Dear Dandy,

 

On behalf of Akorn Pharmaceuticals, I am pleased to offer you
the position of Executive Vice President, Global Quality, reporting to Douglas Boothe, President & CEO.

 

Your anticipated date of employment is dependent on successful
completion of the pre-employment requirements. Your tentative start date is to be determined.

 

Your initial base salary will be at an annual rate of $375,000.00.
You will receive your paycheck every other Friday for the current payroll period. Should Friday fall on a Company holiday, paychecks
will be issued as near as possible to your regularly scheduled payday.

 

You will also be eligible to participate in Akorn’s Performance
Incentive plan, pro-rated based on your start date. Your annual target incentive bonus is 50% of your annual earnings. You will
be eligible to begin participation in plan year 2019. Bonus payments for performance in plan year 2019 will occur March 2020. Eligibility
and payments are governed by the terms of the plan and are subject to approval by the Board of Directors. As Doug’s direct
report, you will also be eligible for an additional 25% of your annual earnings for achievement of corporate defined stretch targets
for fiscal year 2019.

 

The Company will also issue you a one-time, Stock Equity grant
with a value of $750,000. Currently, we expect this grant to be delivered as 50% Restricted Stock Units (RSUs) and 50% Stock Options.

 

You will also be eligible to participate in the Long Term Incentive
Plan (LTIP), reserved for management and exempt employees, which would afford you equity awards on an annual basis.  Any LTIP
awards for which you would be eligible would be determined by the Compensation Committee of the Board of Directors.  Eligibility
to participate in the LTIP would begin in plan year 2019.  Equity earned in plan year 2019 would be granted in 2020.

 

This offer letter is intended to comply with Section 409A of
the Internal Revenue Code (“Section 409A”) or an exemption thereunder and shall be construed and administered in accordance
with Section 409A.

 

Akorn will also provide you with relocation benefits to move
your family and your household goods, if necessary. The relocation benefits would be in accordance with the terms and conditions
of our Relocation Policy. Should you voluntarily leave the company or are terminated for cause within 18 months following your
relocation, you agree to repay the total amount of all expenditures paid to you and to vendors on your behalf.

 

     

     

    

 

 

 

 

You will be eligible for benefits which include medical, dental,
prescription drug, vision, Smart-Choice (Akorn’s (401K) Retirement Savings Program), Education Assistance, flexible spending
accounts, an Employee Assistance Program, life, disability insurance and five (5) weeks of Paid Time Off (PTO), prorated accordingly
for the duration of the calendar year.

 

As a convenience, we will automatically enroll you in Smart
Choice (Akorn’s 401(k) Retirement Savings Plan Program). We will defer four percent (4%) of your pre-tax pay, effective the
first payroll following eligibility; eligibility is defined as the first of the month following your date of hire. Your savings
will be invested in the Fidelity Freedom Funds. You may change or discontinue your deferment at any time and you may move your
savings to different funds once you have begun employment.

 

Your employment at Akorn would be “at-will”, which
means that either you or the Company may terminate employment at any time. Nothing in this letter should be interpreted as a contract
of employment. This offer letter shall be governed by the laws of Illinois, without regard to conflict of law principles.

 

In your position you will be covered under our Executive
and Key Management Change In Control Severance Program. We have included a copy of the program for your reference. This program
is subject to change. Additionally, should your role be eliminated and you are involuntarily terminated without cause, under our
current severance plan you would be eligible for severance equivalent to fifty-two (52) weeks of pay and fifty-two (52) weeks of
benefit continuation along with a pro-rated annual incentive payout. This policy is also subject to change in the future.

 

Our offer of employment will remain open for five days from
the date of this letter and is contingent upon the satisfactory completion of employment eligibility documentation, background
check and drug screen. In addition, you assure us that you are free of any contractual obligations from your current employer or
former employer that will impede your contributions to Akorn.

 

We are confident that you will find your Akorn employment both
challenging and rewarding and that you, in turn, will make significant contributions to our company's success. By signing this
letter in the space below, you are acknowledging that you have read and understood this letter. You are agreeing to and accepting
the terms of the letter and you are not relying on any other representation made by Akorn or its representatives about your employment.
This letter may not be modified, except in writing by authorized Akorn personnel.

 

     

     

    

 

 

 

 

Upon acceptance of this offer, please sign the attached offer
letter, scan and return to me via email. If you have any questions, please do not hesitate to contact me.

 

Sincerely,

 

/s/ Greg Lawless

 

Gregory Lawless

Chief Human Resources Officer

 

 

I accept this offer of employment and understand the terms and
conditions outlined above.

 

 

	/s/ Erislandy Dorado-Boladeres 	 	Feb 11, 2019	 
	Erislandy Dorado-Boladeres	 	DateExhibit 4.1

 

THE BANK OF NEW YORK MELLON

NEW YORK’S FIRST BANK-FOUNDED 1784 BY ALEXANDER HAMILTON

 

 

2 HANSON PLACE, 12TH FLOOR, BROOKLYN,
N.Y. 11217

 

 

 

March 21, 2019

 

Hennion & Walsh, Inc.

2001 Route 46, Waterview Plaza

Parsippany, New Jersey 07054

 

Smart Trust 420 (the “Fund”)

 

Dear Sirs:

The Bank of New York
Mellon is acting as trustee for the Fund, consisting of the unit investment trust (the “Trust”) included in
the Registration Statement relating to the Fund. We enclosed a list of the securities to be deposited in the Trust on the date
hereof. The prices indicated therein reflect our evaluation of such securities as of close of business on March 20, 2019, in accordance
with the valuation method set forth in the applicable Standard Terms and Conditions of Trust and Trust Agreement. We consent to
the reference to The Bank of New York Mellon as the party performing the evaluations of the Trust securities in the Registration
Statement (No. 333-229193) filed with the Securities and Exchange Commission with respect to the registration of the sale of the
Units of the Trust and to the filing of this consent as an exhibit thereto.

 

	 	Very truly yours,	 
	 	 	 
	 	/s/ GERARDO CIPRIANO	 
	 	Gerardo Cipriano	 
	 	Vice PresidentExhibit 4.3

 

Consent of Independent Registered
Public Accounting Firm

We have issued our
report dated March 21, 2019, with respect to the financial statement of Smart Trust 420 contained in Amendment No. 1 to the Registration
Statement on Form S-6 (File No. 333-229193) and related Prospectus. We consent to the use of the aforementioned report in the Registration
Statement and Prospectus, and to the use of our name as it appears under the caption “Independent Registered Public Accounting
Firm”.

 

		/s/
                            Grant Thornton LLP

 

Chicago, Illinois

March 21, 2019Exhibit

Exhibit 10.13

AMENDMENT NO. 1

TO GRIFFIN-AMERICAN HEALTHCARE REIT III, INC.

SECOND AMENDED AND RESTATED SHARE REPURCHASE PLAN

RECITALS

WHEREAS, the Board of Directors (the “Board”) of Griffin-American Healthcare REIT III, Inc., a Maryland corporation (the “Company”), has adopted a Second Amended and Restated Share Repurchase Plan (the “Repurchase Plan”) by which shares (“Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), may be repurchased by the Company from stockholders subject to certain conditions and limitations; and

WHEREAS, the Company has determined to amend the Repurchase Plan to limit the number of the Company’s Shares that will be repurchased during any fiscal quarter to an amount equal to the net proceeds that were received from the sale of Shares of the Company’s Common Stock issued pursuant to the Company’s distribution reinvestment plan (the “Distribution Reinvestment Plan”) during the immediately preceding completed fiscal quarter.

NOW, THEREFORE, the Repurchase Plan is amended as follows:

1.    Defined Terms.  Capitalized terms used but not defined herein shall have the meanings set forth in the Repurchase Plan.

2.    Section 3 of the Repurchase Plan is hereby removed and replaced with the following:

     “3.    Funding and Operations of the Repurchase Plan.     The Company may make purchases pursuant to the Repurchase Plan quarterly, at its sole discretion, on a pro rata basis. The Board shall determine whether the Company has sufficient cash available to make repurchases pursuant to the Repurchase Plan in any given quarter. Subject to funds being available, the Company will limit the number of Shares repurchased to five percent (5.0%) of the weighted average number of Shares outstanding during the calendar year prior to the repurchase date; provided however, that Shares subject to a repurchase requested upon the death or qualifying disability (as defined in the Repurchase Plan) of a stockholder will not be subject to this cap. Furthermore, funding for the Repurchase Plan will come exclusively from cumulative proceeds we receive from the sale of Shares pursuant to the Company’s Distribution Reinvestment Plan, and subject to funds being available, the Company will limit the number of Shares repurchased during any fiscal quarter to an amount equal to the net proceeds that were received from the sale of Shares of the Company’s Common Stock issued pursuant to the Company’s Distribution Reinvestment Plan during the immediately preceding completed fiscal quarter; provided however, that Shares subject to a repurchase requested upon the death or qualifying disability of a stockholder will not be subject to this cap.”

3.    The “Deadline for Presentment” portion of Section 4 of the Repurchase Plan is hereby removed and replaced with the following:

“Deadline for Presentment.     All Shares presented and all completed Share Repurchase Request forms must be received by the Repurchase Agent (as defined below) on or before the last day of the second month of each calendar quarter in order to have such Shares eligible for repurchase for that quarter. The Company will repurchase Shares on or about the first day following the end of each calendar quarter.

If the Company cannot purchase all shares presented for repurchase in any calendar quarter, based upon insufficient cash available and/or the limit on the number of Shares it may repurchase during any calendar year or fiscal quarter, it will attempt to honor repurchase requests on a pro rata basis; provided however, that the Company may give priority to repurchase requests where pro rata repurchases would result in a stockholder owning less than $2,500 of Shares, which may be redeemed in full to the extent there is available cash for such repurchases. The Company will treat the unsatisfied portion of the repurchase request as a request for repurchase the following calendar quarter if sufficient funds are available at that time, unless the requesting stockholder withdraws its request for repurchase. Such pending requests generally will be honored on a pro rata basis. The Company will determine whether it has sufficient funds available as soon as practicable after the end of each calendar quarter, but in any event prior to the applicable payment date.”

4.    Continuing Effect.  Except as otherwise set forth in this Amendment No. 1 to Second Amended and Restated Share Repurchase Plan, the terms of the Repurchase Plan shall continue in full force and effect and shall not be deemed to have otherwise been amended, modified, revised or altered.

5.    Effective Date.  This Amendment No. 1 to Second Amended and Restated Share Repurchase Plan shall be effective commencing with respect to share repurchase requests submitted for repurchase during the second quarter 2019.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]